adenocarcinoma

Documents about adenocarcinoma

• Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma#160365ClinicalTrials.gov
• Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma#850617ClinicalTrials.gov
• Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma#429753ClinicalTrials.gov
• Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma#245512ClinicalTrials.gov
• Perioperative Chemo and Pembrolizumab in Gastric Cancer#841088ClinicalTrials.gov
• Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma#460077ClinicalTrials.gov
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study#321720ClinicalTrials.gov
• Evaluation of Tumor Budding In Colorectal Adenocarcinoma#872238ClinicalTrials.gov
• Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection#148725ClinicalTrials.gov
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)#835494ClinicalTrials.gov
• MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer#825086ClinicalTrials.gov
• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery#136301ClinicalTrials.gov
• Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice#803308ClinicalTrials.gov
• Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma#851920ClinicalTrials.gov
• Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma#867375ClinicalTrials.gov
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers#837064ClinicalTrials.gov
• Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma#181778ClinicalTrials.gov
• Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma#230402ClinicalTrials.gov
• Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma#353277ClinicalTrials.gov
• Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer#836740ClinicalTrials.gov
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers#828464ClinicalTrials.gov
• OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma#840055ClinicalTrials.gov
• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer#833149ClinicalTrials.gov
• Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene#870060ClinicalTrials.gov
• Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma#160374ClinicalTrials.gov
• ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study#845246ClinicalTrials.gov
• ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features#845355ClinicalTrials.gov
• Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms#141069ClinicalTrials.gov
• Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma#802640ClinicalTrials.gov
• Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis#848595ClinicalTrials.gov
• RT for Adenocarcinoma/Adenosquamous Carcinoma#141013ClinicalTrials.gov
• Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ#346931ClinicalTrials.gov
• Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma#411374ClinicalTrials.gov
• Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma#849550ClinicalTrials.gov
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer#162449ClinicalTrials.gov
• Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer#154642ClinicalTrials.gov
• Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma#808030ClinicalTrials.gov
• HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia#860734ClinicalTrials.gov
• Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma#862366ClinicalTrials.gov
• How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery#840624ClinicalTrials.gov
• Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma#353294ClinicalTrials.gov
• A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma#234424ClinicalTrials.gov
• BATs Treatment for Pancreatic Cancer, Phase Ib/II#426795ClinicalTrials.gov
• Bethanechol Prior to Pancreatic Surgery#861634ClinicalTrials.gov
• Impacto del patrón de vascularización tumoral en el microambiente inmunitario del adenocarcinoma pulmonar#433232Gestión del Repositorio Documental de la Universidad de Salamanca
• Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas#833780ClinicalTrials.gov
• Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma#871469ClinicalTrials.gov
• Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma#871703ClinicalTrials.gov
• A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma#683128ClinicalTrials.gov
• Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma#850494ClinicalTrials.gov